{
    "hands_on_practices": [
        {
            "introduction": "A cornerstone of clinical neurology is the ability to correlate anatomical structures with clinical signs and symptoms. This practice challenges you to apply your knowledge of spinal cord neuroanatomy to a realistic case of transverse myelitis. By starting from the precise location of a lesion on an MRI, you will deduce the expected pattern of motor, sensory, and autonomic dysfunction, sharpening your skills in clinical localization .",
            "id": "4531542",
            "problem": "A $32$-year-old individual presents with acute midline thoracic pain, followed by rapidly evolving bilateral sensory changes over the trunk and mild proximal trunk weakness. Magnetic Resonance Imaging (MRI) of the thoracic spinal cord shows an axial T2-weighted hyperintense lesion at the $T_{10}$ level, centered on the central gray matter and the adjacent anterior white commissure, with relative sparing of the peripheral lateral white matter. Cerebrospinal fluid analysis reveals pleocytosis, consistent with inflammatory Transverse Myelitis.\n\nUsing only core neuroanatomical and neurophysiological principles, predict the most likely pattern of clinical motor and sensory signs at and below the lesion, as well as the expected time course of bladder dysfunction, and justify the prediction by deriving it from first principles. Select the one option that best matches the expected findings.\n\nFundamental starting points:\n- Segmental organization: spinal cord segments at $T_{10}$ innervate the $T_{10}$ dermatomal band (approximately the periumbilical region), and anterior horn cells at $T_{10}$ subserve segmental motor output to intercostal and abdominal musculature at the corresponding level.\n- Pain and temperature transmission: primary afferents enter the dorsal horn, synapse, and secondary neurons cross the midline in the anterior white commissure over approximately $1$–$2$ segments before ascending in the contralateral anterolateral system (spinothalamic tract).\n- Touch, vibration, and proprioception transmission: dorsal column (gracile and cuneate fasciculi) fibers ascend ipsilaterally without crossing in the spinal cord.\n- Voluntary motor control: corticospinal tract fibers descend in the lateral funiculus; damage yields upper motor neuron signs below the lesion, while anterior horn damage yields lower motor neuron signs at the lesion level.\n- Micturition control: the pontine micturition center and supraspinal descending pathways modulate sacral parasympathetic outflow ($S_{2}$–$S_{4}$); acute spinal cord lesions above $S_{2}$–$S_{4}$ cause an initial phase of “spinal shock” with detrusor areflexia and urinary retention, followed by a chronic phase of hyperreflexic (spastic) bladder with detrusor–sphincter dyssynergia once spinal reflexes return. Sympathetic contribution to storage arises from $T_{11}$–$L_{2}$ intermediolateral cell column.\n\nWhich option is most consistent with the described lesion?\n\nA. Band-like bilateral loss of pain and temperature at the $T_{10}$ dermatomes with preservation of vibration and proprioception, segmental lower motor neuron weakness of trunk musculature at $T_{10}$, and bladder retention acutely (areflexic detrusor) evolving to hyperreflexic urgency and detrusor–sphincter dyssynergia over weeks.\n\nB. Spastic paraparesis with bilateral Babinski signs immediately below $T_{10}$, loss of vibration and proprioception below $T_{10}$ with preserved pain and temperature, and immediate urge incontinence due to detrusor overactivity without a phase of retention.\n\nC. Dissociated sensory loss characterized by preserved pain and temperature with loss of vibration at the $T_{10}$ band, lower motor neuron weakness in the legs due to anterior horn involvement, and a chronically atonic bladder due to loss of parasympathetic sacral outflow.\n\nD. Brown-Séquard syndrome pattern: ipsilateral loss of vibration and proprioception with contralateral loss of pain and temperature below $T_{10}$, ipsilateral upper motor neuron weakness, and urinary frequency primarily due to loss of sympathetic storage pathways at $T_{10}$.\n\nE. Anterior spinal artery infarct pattern at $T_{10}$ with bilateral flaccid paraplegia evolving to spasticity, loss of pain and temperature below the lesion with preserved vibration, and a permanently areflexic bladder due to interruption of sacral reflex arcs.",
            "solution": "The user has provided a clinical vignette and a set of fundamental neuroanatomical principles, tasking me with validating the problem and then using those principles to deduce the correct clinical presentation.\n\n### Step 1: Extract Givens\n\n-   **Patient Profile**: A $32$-year-old individual.\n-   **Clinical Presentation**: Acute midline thoracic pain, rapidly evolving bilateral sensory changes over the trunk, and mild proximal trunk weakness.\n-   **Imaging**: Magnetic Resonance Imaging (MRI) shows an axial T2-weighted hyperintense lesion at the $T_{10}$ spinal cord level. The lesion is centered on the central gray matter and the adjacent anterior white commissure. There is relative sparing of the peripheral lateral white matter.\n-   **Lab Findings**: Cerebrospinal fluid (CSF) analysis reveals pleocytosis, consistent with inflammatory Transverse Myelitis.\n-   **Provided First Principles**:\n    1.  **Segmental Organization**: The $T_{10}$ spinal segment innervates the $T_{10}$ dermatome (periumbilical region) and contains anterior horn cells for segmental motor output (intercostal/abdominal muscles).\n    2.  **Pain and Temperature Pathway (Anterolateral System)**: Second-order neurons cross the midline in the anterior white commissure over $1$–$2$ segments before ascending.\n    3.  **Touch, Vibration, Proprioception Pathway (Dorsal Columns)**: These fibers ascend ipsilaterally without crossing in the spinal cord.\n    4.  **Motor Pathway**: The corticospinal tract descends in the lateral funiculus (damage causes upper motor neuron signs below the lesion). Anterior horn cells are lower motor neurons (damage causes lower motor neuron signs at the lesion level).\n    5.  **Micturition Control**: Acute lesions above the sacral parasympathetic center ($S_{2}$–$S_{4}$) cause initial \"spinal shock\" with detrusor areflexia and urinary retention, followed by a chronic phase of hyperreflexic bladder with detrusor–sphincter dyssynergia.\n\n### Step 2: Validate Using Extracted Givens\n\nThe problem statement will be evaluated for validity.\n\n-   **Scientific Groundedness**: The problem describes a classic neurological syndrome. The clinical presentation, MRI findings, and CSF results are internally consistent and represent a plausible case of transverse myelitis with features of a central cord syndrome. The provided neuroanatomical and physiological principles are standard, foundational knowledge in neuroscience. The problem is scientifically sound.\n-   **Well-Posedness**: The problem is well-posed. The location of the lesion is specified with adequate precision (level $T_{10}$, central gray matter, anterior white commissure, sparing of peripheral white matter). This information is sufficient to deduce a specific set of clinical deficits by applying the given first principles. A unique and meaningful solution can be derived.\n-   **Objectivity**: The description is clinical, objective, and free from subjective or ambiguous language.\n\nThe problem statement does not violate any of the invalidity criteria. It is a valid, solvable problem based on the direct application of fundamental neuroanatomical principles.\n\n### Step 3: Derivation of the Solution\n\nThe lesion is located at the $T_{10}$ level and specifically affects the **central gray matter** and the **anterior white commissure**, with relative sparing of the peripheral white matter tracts. We will analyze the consequences of damaging each of these structures based on the provided principles.\n\n1.  **Damage to the Anterior White Commissure at $T_{10}$**:\n    -   The anterior white commissure contains the decussating (crossing) axons of second-order neurons from the spinothalamic tracts. These tracts convey pain and temperature sensation.\n    -   Since these fibers cross the midline, a central lesion will damage fibers from both the left and right sides of the body at the level of the lesion.\n    -   The fibers crossing at $T_{10}$ originate from dorsal horns at approximately the $T_{10}$ level (and slightly below, given the $1$–$2$ segment ascent before crossing).\n    -   Therefore, the predicted sensory deficit is a **bilateral loss of pain and temperature sensation** in a band-like pattern corresponding to the $T_{10}$ dermatomes.\n\n2.  **Sparing of the Dorsal Columns**:\n    -   The dorsal columns (fasciculus gracilis and cuneatus) are located in the most posterior part of the spinal cord. The lesion is described as central and anterior.\n    -   These tracts carry vibration and proprioception. Since they are anatomically distant from the lesion, these modalities should be **preserved** throughout the body.\n    -   The combination of pain/temperature loss with preserved vibration/proprioception is known as \"dissociated sensory loss.\"\n\n3.  **Damage to the Central Gray Matter (Anterior Horns) at $T_{10}$**:\n    -   The anterior horns contain the cell bodies of lower motor neurons (LMNs).\n    -   At the $T_{10}$ level, these LMNs innervate the segmental musculature, which includes the lower intercostal and abdominal wall muscles.\n    -   Damage to these cells will result in **LMN-type weakness** (flaccid weakness) of the trunk muscles at the $T_{10}$ level. This precisely matches the \"mild proximal trunk weakness\" described in the presentation.\n\n4.  **Sparing of the Peripheral Lateral White Matter**:\n    -   The lateral corticospinal tracts, which are the primary pathways for voluntary motor control to the limbs, are located in the peripheral part of the lateral funiculus.\n    -   The problem states these areas are **relatively spared**.\n    -   Therefore, significant upper motor neuron (UMN) signs below the lesion, such as spastic paraparesis or Babinski signs in the legs, are **not expected**.\n\n5.  **Bladder Dysfunction**:\n    -   The lesion is at $T_{10}$, which is superior to the sacral spinal cord segments ($S_{2}$–$S_{4}$) that control the bladder reflex arc.\n    -   According to the provided micturition principles, an acute, significant lesion above the sacral cord interrupts descending control pathways, leading to a state of **spinal shock**.\n    -   In the acute phase (days to weeks), spinal shock causes the detrusor muscle of the bladder to be areflexic (atonic). This results in an inability to void and leads to **urinary retention**.\n    -   In the chronic phase (weeks to months), spinal reflexes below the lesion return and become hyperactive due to the loss of supraspinal inhibition. This results in a **hyperreflexic (spastic) bladder**, characterized by involuntary detrusor contractions, urinary urgency, and frequency. This is often complicated by **detrusor–sphincter dyssynergia**, where the external sphincter fails to relax during bladder contraction, leading to inefficient emptying and high pressures.\n\n**Summary of Predicted Findings**:\nThe patient should exhibit a band-like bilateral loss of pain and temperature at the $T_{10}$ level, with preserved vibration and proprioception. Motor findings should be limited to LMN weakness of the trunk muscles at the $T_{10}$ level. Bladder function should follow a two-phase course: acute urinary retention followed by chronic hyperreflexic bladder and urgency.\n\n### Evaluation of Options\n\n**A. Band-like bilateral loss of pain and temperature at the $T_{10}$ dermatomes with preservation of vibration and proprioception, segmental lower motor neuron weakness of trunk musculature at $T_{10}$, and bladder retention acutely (areflexic detrusor) evolving to hyperreflexic urgency and detrusor–sphincter dyssynergia over weeks.**\n-   This option perfectly aligns with our derivation. It correctly identifies the dissociated sensory loss pattern from a central cord lesion, the segmental LMN weakness from anterior horn involvement, the sparing of dorsal columns, and the classic two-phase bladder dysfunction following a suprasacral spinal cord injury.\n-   **Verdict: Correct.**\n\n**B. Spastic paraparesis with bilateral Babinski signs immediately below $T_{10}$, loss of vibration and proprioception below $T_{10}$ with preserved pain and temperature, and immediate urge incontinence due to detrusor overactivity without a phase of retention.**\n-   This describes major corticospinal tract and dorsal column damage, which contradicts the lesion's location and the stated sparing of peripheral white matter. The sensory deficit is inverted. The bladder description misses the acute spinal shock phase.\n-   **Verdict: Incorrect.**\n\n**C. Dissociated sensory loss characterized by preserved pain and temperature with loss of vibration at the $T_{10}$ band, lower motor neuron weakness in the legs due to anterior horn involvement, and a chronically atonic bladder due to loss of parasympathetic sacral outflow.**\n-   The sensory loss is a posterior cord pattern, not a central one. LMN weakness in the legs would require a lumbosacral lesion, not a $T_{10}$ lesion. A chronically atonic bladder implies damage to the sacral cord itself, whereas a suprasacral lesion leads to a chronic hyperreflexic bladder.\n-   **Verdict: Incorrect.**\n\n**D. Brown-Séquard syndrome pattern: ipsilateral loss of vibration and proprioception with contralateral loss of pain and temperature below $T_{10}$, ipsilateral upper motor neuron weakness, and urinary frequency primarily due to loss of sympathetic storage pathways at $T_{10}$.**\n-   This describes a hemicord lesion, not the central, bilateral lesion described. The bladder explanation is also incomplete and misleading.\n-   **Verdict: Incorrect.**\n\n**E. Anterior spinal artery infarct pattern at $T_{10}$ with bilateral flaccid paraplegia evolving to spasticity, loss of pain and temperature below the lesion with preserved vibration, and a permanently areflexic bladder due to interruption of sacral reflex arcs.**\n-   While the sensory pattern is partially correct for an anterior cord syndrome, this option incorrectly predicts bilateral paraplegia (implicating the corticospinal tracts, which are spared here) and a permanently areflexic bladder (which would require a sacral cord lesion). The lesion described is a central cord syndrome, which is less extensive than a typical anterior spinal artery infarct.\n-   **Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "While imaging localizes a lesion, laboratory analysis of cerebrospinal fluid (CSF) is critical for determining its inflammatory nature. This exercise focuses on the IgG index, a key quantitative marker for intrathecal immunoglobulin synthesis. You will first calculate the index from raw lab data and then use Bayes' theorem to determine the post-test probability of disease, a powerful skill for evidence-based diagnostic reasoning .",
            "id": "5213255",
            "problem": "A 10-year-old child presents with acute inflammatory myelopathy consistent with transverse myelitis. Cerebrospinal fluid (CSF) and serum studies are obtained. Using the core definition that the immunoglobulin G (IgG) index is the quotient of the CSF-to-serum IgG ratio divided by the CSF-to-serum albumin ratio, compute the IgG index from the following measured concentrations: CSF immunoglobulin G (IgG) is $60$ mg/L, serum IgG is $8$ g/L, CSF albumin is $200$ mg/L, and serum albumin is $40$ g/L. Then, in a separate child of the same age with clinically similar acute myelitis, the IgG index is directly measured at $1.2$. Assuming a diagnostic threshold of $0.7$ for a positive test for intrathecal IgG synthesis, a sensitivity of $0.72$, and a specificity of $0.94$ for this threshold in pediatric inflammatory myelopathies, and a pre-test probability of intrathecal IgG synthesis of $0.25$ in this clinical context, use first principles of probability to compute the post-test probability of intrathecal IgG synthesis for the child with an IgG index of $1.2$. Express the final answer as a decimal and round to four significant figures. No units are required for the final answer.",
            "solution": "The problem presents a two-part task. First, it requires the calculation of the Immunoglobulin G (IgG) index for a patient from given laboratory data. Second, it asks for the calculation of the post-test probability of a condition in a second patient, based on a given test result and test characteristics.\n\nFirst, we compute the IgG index for the first child, a $10$-year-old. The definition of the IgG index is provided as the quotient of the CSF-to-serum IgG ratio divided by the CSF-to-serum albumin ratio.\nLet $\\text{IgG}_{CSF}$ and $\\text{IgG}_{serum}$ be the concentrations of IgG in cerebrospinal fluid (CSF) and serum, respectively.\nLet $\\text{Alb}_{CSF}$ and $\\text{Alb}_{serum}$ be the concentrations of albumin in CSF and serum, respectively.\nThe formula for the IgG index is:\n$$ \\text{IgG Index} = \\frac{\\left( \\frac{\\text{IgG}_{CSF}}{\\text{IgG}_{serum}} \\right)}{\\left( \\frac{\\text{Alb}_{CSF}}{\\text{Alb}_{serum}} \\right)} $$\nThe provided laboratory values are:\n$\\text{IgG}_{CSF} = 60 \\text{ mg/L}$\n$\\text{IgG}_{serum} = 8 \\text{ g/L}$\n$\\text{Alb}_{CSF} = 200 \\text{ mg/L}$\n$\\text{Alb}_{serum} = 40 \\text{ g/L}$\n\nFor the calculation to be dimensionally consistent, the units of concentration for CSF and serum must be the same. We will convert the serum concentrations from g/L to mg/L using the conversion factor $1 \\text{ g} = 1000 \\text{ mg}$.\n$$ \\text{IgG}_{serum} = 8 \\frac{\\text{g}}{\\text{L}} \\times \\frac{1000 \\text{ mg}}{1 \\text{ g}} = 8000 \\frac{\\text{mg}}{\\text{L}} $$\n$$ \\text{Alb}_{serum} = 40 \\frac{\\text{g}}{\\text{L}} \\times \\frac{1000 \\text{ mg}}{1 \\text{ g}} = 40000 \\frac{\\text{mg}}{\\text{L}} $$\nSubstituting these consistent values into the formula for the IgG index:\n$$ \\text{IgG Index} = \\frac{\\left( \\frac{60 \\text{ mg/L}}{8000 \\text{ mg/L}} \\right)}{\\left( \\frac{200 \\text{ mg/L}}{40000 \\text{ mg/L}} \\right)} = \\frac{0.0075}{0.005} = 1.5 $$\nThe IgG index for the first child is $1.5$. This part of the problem serves as a contextual prelude to the primary question.\n\nNext, we proceed to the second part of the problem, which is to calculate the post-test probability of intrathecal IgG synthesis for a separate child. This is a classic application of Bayes' theorem. Let us define the following events:\n$D$: The event that the child has intrathecal IgG synthesis.\n$D^c$: The complement of $D$; i.e., the child does not have intrathecal IgG synthesis.\n$T^+$: The event of a positive test result (IgG index is greater than the diagnostic threshold).\n$T^-$: The event of a negative test result.\n\nThe problem provides the following probabilities:\nThe pre-test probability of the condition: $P(D) = 0.25$.\nThe sensitivity of the test: $P(T^+ | D) = 0.72$.\nThe specificity of the test: $P(T^- | D^c) = 0.94$.\n\nThe second child has a measured IgG index of $1.2$. The diagnostic threshold is $0.7$. Since $1.2 > 0.7$, the test result for this child is positive, which corresponds to the event $T^+$. We are required to compute the post-test probability of the condition given this positive result, which is denoted as $P(D | T^+)$.\n\nBayes' theorem is stated as:\n$$ P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)} $$\nThe denominator, $P(T^+)$, is the total probability of obtaining a positive test result. This is found using the law of total probability:\n$$ P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c) $$\nTo find $P(T^+)$, we first need values for $P(D^c)$ and $P(T^+ | D^c)$.\nThe probability of not having the condition, $P(D^c)$, is the complement of the probability of having it:\n$$ P(D^c) = 1 - P(D) = 1 - 0.25 = 0.75 $$\nThe term $P(T^+ | D^c)$ represents the false positive rate, which is the complement of the specificity, $P(T^- | D^c)$:\n$$ P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - 0.94 = 0.06 $$\nNow we can calculate the total probability of a positive test, $P(T^+)$:\n$$ P(T^+) = (0.72)(0.25) + (0.06)(0.75) $$\n$$ P(T^+) = 0.18 + 0.045 = 0.225 $$\nFinally, we substitute the known quantities back into Bayes' theorem to find the post-test probability:\n$$ P(D | T^+) = \\frac{P(T^+ | D) P(D)}{P(T^+)} = \\frac{(0.72)(0.25)}{0.225} = \\frac{0.18}{0.225} $$\n$$ P(D | T^+) = 0.8 $$\nThe problem specifies that the final answer should be expressed as a decimal rounded to four significant figures. Therefore, the value $0.8$ is written as $0.8000$.",
            "answer": "$$\\boxed{0.8000}$$"
        },
        {
            "introduction": "Once a diagnosis of inflammatory transverse myelitis is established, initiating treatment is the next critical step. This problem focuses on the practical pharmacology of high-dose intravenous glucocorticoids, the first-line therapy. You will derive a dosing function that accounts for weight-based calculations and protocol-mandated maximums, a common real-world scenario that blends mathematical precision with clinical practice .",
            "id": "4531452",
            "problem": "A pediatric patient presents with acute transverse myelitis, a segmental inflammatory lesion of the spinal cord within the central nervous system (CNS), for which high-dose intravenous (IV) glucocorticoid therapy is initiated. The hospital protocol specifies daily methylprednisolone at $30\\ \\text{mg/kg/day}$ with a maximum cap of $1\\ \\text{g/day}$. Starting only from the foundational rule that weight-based dosing multiplies a per-kilogram daily rate by body mass, and applying dimensional analysis to convert milligrams to grams, derive a closed-form analytic expression for the daily dose $D(m)$ in grams per day as a function of the child’s body mass $m$ (in kilograms) that adheres to the maximum daily cap. Do not assume any empirical shortcut formula beyond these bases. In your derivation, identify the mass threshold at which the cap becomes active and explain the mathematical structure of the dose function.\n\nAdditionally, outline a scientifically realistic inpatient monitoring plan tailored to high-dose glucocorticoid therapy in pediatric transverse myelitis, covering cardiovascular, metabolic, infectious, gastrointestinal, and neurologic domains, with reasonable measurement frequencies grounded in physiology and pharmacology. This plan should be justified but will not be part of the final numeric answer.\n\nExpress the final dose $D(m)$ in grams per day. No rounding is required, and the final answer must be a single closed-form analytic expression in terms of $m$.",
            "solution": "The problem statement has been evaluated and is deemed valid. It is scientifically grounded in established principles of clinical pharmacology and neurology, is well-posed with sufficient information for a unique solution, and is expressed in objective, precise language. All conditions for a valid problem are met.\n\nThe task is to derive a closed-form analytic expression for the daily dose $D(m)$ of methylprednisolone in grams per day for a pediatric patient of mass $m$ in kilograms. A secondary task is to outline a corresponding inpatient monitoring plan.\n\nFirst, we derive the dose function $D(m)$. The foundational rule for weight-based dosing states that the provisional dose, which we will call $D_{\\text{wb}}$, is the product of the prescribed rate per unit mass and the total body mass.\n\nThe given rate is $r = 30\\ \\text{mg/kg/day}$.\nThe patient's mass is $m$, with units of kilograms ($kg$).\n\nThe provisional daily dose in milligrams is thus:\n$$D_{\\text{wb, mg}}(m) = r \\times m = \\left(30\\ \\frac{\\text{mg}}{\\text{kg} \\cdot \\text{day}}\\right) \\times (m\\ \\text{kg}) = 30m\\ \\frac{\\text{mg}}{\\text{day}}$$\n\nThe problem requires the final dose $D(m)$ to be expressed in grams per day ($g/day$). We apply dimensional analysis using the conversion factor $1\\ \\text{g} = 1000\\ \\text{mg}$.\n$$D_{\\text{wb}}(m) = (30m\\ \\frac{\\text{mg}}{\\text{day}}) \\times \\left(\\frac{1\\ \\text{g}}{1000\\ \\text{mg}}\\right) = \\frac{30m}{1000}\\ \\frac{\\text{g}}{\\text{day}} = \\frac{3m}{100}\\ \\frac{\\text{g}}{\\text{day}}$$\nFor the remainder of the derivation, we will work with the numerical value of the dose in grams, $\\frac{3m}{100}$.\n\nThe hospital protocol specifies a maximum daily dose, or cap, of $D_{\\text{max}} = 1\\ \\text{g/day}$. This means the administered dose $D(m)$ cannot exceed this value, regardless of the patient's mass. The actual dose is therefore the lesser of the calculated weight-based dose and the maximum allowed dose. This is mathematically represented by the minimum function:\n$$D(m) = \\min(D_{\\text{wb}}(m), D_{\\text{max}})$$\nSubstituting the derived expressions:\n$$D(m) = \\min\\left(\\frac{3m}{100}, 1\\right)$$\nThis is the single closed-form analytic expression for the dose in grams per day.\n\nTo understand the mathematical structure of this function, we must identify the mass threshold at which the cap becomes active. This threshold, which we denote $m_{\\text{threshold}}$, is the mass for which the weight-based dose is exactly equal to the maximum dose.\n$$D_{\\text{wb}}(m_{\\text{threshold}}) = D_{\\text{max}}$$\n$$\\frac{3m_{\\text{threshold}}}{100} = 1$$\nSolving for $m_{\\text{threshold}}$:\n$$m_{\\text{threshold}} = \\frac{100}{3}\\ \\text{kg}$$\nNumerically, $m_{\\text{threshold}} \\approx 33.33\\ \\text{kg}$.\n\nThe structure of the dose function $D(m)$ can now be described as a piecewise function:\n1.  For a patient with mass $m \\le m_{\\text{threshold}}$ (i.e., $m \\le \\frac{100}{3}\\ \\text{kg}$), the dose is determined by the linear weight-based calculation: $D(m) = \\frac{3m}{100}$. In this domain, the dose increases linearly with mass.\n2.  For a patient with mass $m > m_{\\text{threshold}}$ (i.e., $m > \\frac{100}{3}\\ \\text{kg}$), the calculated weight-based dose would exceed the cap. Therefore, the dose is fixed at the maximum value: $D(m) = 1$. In this domain, the dose is a constant function.\n\nGraphically, the function $D(m)$ is a ramp function that increases linearly from the origin with a slope of $\\frac{3}{100}$ until it reaches a value of $1$ at $m = \\frac{100}{3}$, after which it remains constant at $1$. This function is continuous for all $m > 0$.\n\nAdditionally, a scientifically realistic inpatient monitoring plan for a pediatric patient on high-dose glucocorticoid therapy is as follows:\n\n1.  **Cardiovascular Monitoring:**\n    *   **Action:** Monitor blood pressure and heart rate every $4$-$6$ hours.\n    *   **Justification:** Glucocorticoids have mineralocorticoid effects, leading to sodium and water retention, which can cause hypertension. Tachycardia can also occur.\n    *   **Action:** Check serum electrolytes (sodium, potassium, bicarbonate) daily.\n    *   **Justification:** The mineralocorticoid activity can also lead to hypokalemic metabolic alkalosis.\n\n2.  **Metabolic Monitoring:**\n    *   **Action:** Monitor blood glucose levels via point-of-care testing every $6$ hours (e.g., before meals and at bedtime).\n    *   **Justification:** High-dose glucocorticoids induce insulin resistance and increase gluconeogenesis, leading to a high risk of hyperglycemia, even in patients without a history of diabetes.\n\n3.  **Infectious Disease Monitoring:**\n    *   **Action:** Monitor temperature every $4$-$6$ hours. Perform daily clinical assessment for signs of infection (e.g., lethargy, cough, dysuria).\n    *   **Justification:** Glucocorticoids are potent immunosuppressants, increasing susceptibility to bacterial, viral, and fungal infections. They can also mask fever, so a high index of suspicion is required.\n\n4.  **Gastrointestinal Monitoring:**\n    *   **Action:** Daily inquiry for symptoms of dyspepsia, epigastric pain, nausea, or vomiting. Monitor stools for evidence of bleeding (melena).\n    *   **Justification:** Glucocorticoids can impair the protective mucosal barrier of the stomach and increase gastric acid secretion, raising the risk of gastritis and peptic ulcer disease. Prophylactic acid suppression with a proton pump inhibitor or H2-receptor antagonist is often co-administered.\n\n5.  **Neurologic and Psychiatric Monitoring:**\n    *   **Action:** Perform a detailed daily neurologic examination, specifically assessing motor strength, sensory levels, and autonomic function (bowel/bladder control).\n    *   **Justification:** This is essential to track the efficacy of the treatment for the primary diagnosis of transverse myelitis.\n    *   **Action:** Daily assessment of mood, behavior, and sleep patterns.\n    *   **Justification:** High-dose steroids can cause significant neuropsychiatric side effects, including insomnia, agitation, emotional lability, mania, or psychosis (\"steroid psychosis\").",
            "answer": "$$\\boxed{\\min\\left(\\frac{3m}{100}, 1\\right)}$$"
        }
    ]
}